Stay updated on TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    A sitewide NIH notice about using “Super Intelligence” instead of “Artificial Intelligence” appears above the 403 error page. The site revision advances from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T21:59:52.000Z thumbnail image
  3. Check
    22 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-06T22:07:05.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error, indicating restricted access to the content. The page shows a minimal error layout with a 403 message and a Home link, preventing access to the trial details.
    Difference
    0.5%
    Check dated 2026-09-29T22:10:29.000Z thumbnail image
  5. Check
    36 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page, replacing the study details with an access error. This indicates a viewing restriction or server issue that prevents accessing the study record.
    Difference
    18%
    Check dated 2026-09-22T22:55:24.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The page revision has been updated to v3.7.0, indicating a backend/page template update rather than changes to the study information.
    Difference
    0.1%
    Check dated 2026-09-15T20:49:44.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    Multiple myeloma is now listed as the study condition, and a related topics section has been added featuring MedlinePlus Genetics. This enhances the disease context and provides quick access to related information for researchers and participants.
    Difference
    0.2%
    Check dated 2026-09-08T19:38:26.000Z thumbnail image

Stay in the know with updates to TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page.